CoChat

Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials

Open access
du Bois, Roland M., Nathan, Steven D., Richeldi, Luca, Schwarz, Marvin I., Noble, Paul W. · 2012 · American Journal of Respiratory and Critical Care Medicine
Cited by 95

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Idiopathic pulmonary fibrosis causes progressive morbidity and has a worldwide incidence that is increasing. There are a number of promising therapies, one of which has been approved in Europe, parts of Asia, and India, and others that are at various stages of development. Despite this, there continues to be debate about the most appropriate clinical endpoint that should be used in future randomized controlled clinical trials of novel therapies in idiopathic pulmonary fibrosis. In a recent Pulmonary Perspective in this journal, the case for the use of a variety of clinical endpoints was analyzed, and the article concluded that FVC, the endpoint most commonly used recently and in ongoing studies, was not an appropriate option. In this Pulmonary Perspective we present a counterpoint in which we explore the basis on which this conclusion is drawn and present data that strongly and logically support the use of FVC as a valid and robust measure that fulfils the criteria for an ideal clinical endpoint and that is meaningful to patient and clinician alike.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201206-1010pp

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 95

Metadata

Authors
du Bois, R. M., Nathan, S. D., Richeldi, L., Schwarz, M. I., & Noble, P. W.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2012-10-15
Volume
186
Issue
8
Pages
712-715
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2003201331
Cited by
95
References
3
FWCI
10.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials. https://app.cochat.ai/papers/10.1164/rccm.201206-1010pp
The paper
du Bois, R. M., Nathan, S. D., Richeldi, L., Schwarz, M. I., & Noble, P. W. (2012). Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201206-1010pp

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.